Denali Therapeutics Inc. (DNLI) reported revenue of $0 for fiscal 2024, the year ended 31 December 2024. Net income was -$423 million, and diluted earnings per share $-2.57. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2025.
Revenue
$0
FY2017FY2024
Operating margin
n/a
-59.5% a year earlier
FY2017FY2024
Net income
-$423 million
FY2017FY2024
Diluted EPS
-$2.57
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-348
-358
-245
Capital expenditure
15.9
12.9
17.8
+23.0%
Free cash flow
-364
-371
-263
Free cash flow margin
n/a
-112.2%
-242.1%
Cash from investing
-88.8
249
-141
Cash from financing
484
17.8
311
+2,617.8%
Depreciation and amortisation
7.8
16.7
10.4
-53.4%
Share-based compensation
103
108
99.8
-4.8%
Diluted shares, weighted
164m
137m
126m
+19.7%
Shares outstanding at period end
144m
138m
136m
+4.2%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
1,230
1,031
1,042
+19.3%
Debt
0.0
0.0
0.0
Operating lease liabilities
36.7
45.0
53.0
-18.5%
Finance lease liabilities
5.6
0.0
n/a
Other liabilities
102
78.0
365
+31.1%
Total liabilities and equity
1,374
1,154
1,460
+19.1%
Fixed assets
55.2
45.6
44.1
+21.2%
Investments
1,017
907
1,118
+12.0%
Cash and equivalents
175
127
218
+37.6%
Other assets
127
73.8
79.9
+72.4%
Total assets
1,374
1,154
1,460
+19.1%
10-K for the year ended 31 December 2024, filed 27 February 2025: the filing.